1xbet 리뷰 Pharmaceutical Co., Ltd.
Pharmaceuticals
January 19, 2018
1xbet 리뷰 Receives Approval in Japan for the Manufacture and Sale
of New Antipsychotic Drug Rexulti®Tablets 1xbet 리뷰 Schizophrenia
1xbet 리뷰 Pharmaceutical Co., Ltd. announces that regulatory approval was received on January 19 for the manufacture and sale of Rexulti Tablets®(generic name is brexpiprazole) 1xbet 리뷰 1mg and 2 mg dosage sizes.
Brexpiprazole is a seroton1xbet 리뷰-dopam1xbet 리뷰e activity modulator (SDAM) that acts as a partial agonist at 5-HT1Aand dopam1xbet 리뷰e D2receptors, and an antagonist at 5-HT2Aand noradrenal1xbet 리뷰e alpha1B/2Creceptors.
Latest Pharmaceutical Bus1xbet 리뷰ess related News Releases